Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Posts Double-Digit Growth in Q2 Revenues, Profit

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its second-quarter revenues rose 10.9 percent on double-digit growth in its Diagnostics and Biosciences segments, and 13.9 percent profit growth for the three-month period ended March 31.
 
The Franklin Lakes, NJ-based medical devices, diagnostics, and research products firm generated second-quarter revenues of $1.7 billion compared to $1.6 billion in the second quarter of 2007. Sales for the BD Medical segment rose 9.3 percent to $922.3 million; sales for BD Diagnostics climbed 12.1 percent to $530.6 million; and sales for BD Biosciences increased 13.8 percent to $294.1 million.
 
During a conference call today, BD EVP Vince Forlenza said that molecular diagnostics business GeneOhm Sciences, which BD purchased two years ago for $230 million, brought in $10 million in revenues during the quarter. He said the firm expects GeneOhm to contribute around $40 million for fiscal 2008.
 
BD posted a profit of $276.2 million, or $1.09 per share, compared to a profit of $242.5 million, or $.92 per share, in the second quarter of 2007.
 
The firm’s R&D costs rose 10.8 percent to $96 million from $86.7 million year over year, and its SG&A costs inched up 2.2 percent to $415.5 million from $406.6 million.
 
BD did not provide its cash position as of the end of the quarter.
 
In late Wednesday trade on the New York Stock Exchange, shares of BD were up 1.9 percent at $86.22.
 
 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.